Loading...

VERO VENUS CONCEPT INC Product Launches 8-K Filing

VNS

VR

VENUS CONCEPT INC

(VERO)

2025 8-K

Financial Agreement Update

FDA Clearance Achieved

Loan Agreement Update

Exchange Agreement Signed

Financing Update

Loan Amendments

Loan Agreement Update

Financial Results Release

Debt Restructuring

Debt-Equity Swaps

Debt Restructuring

Equity Offerings

Asset Acquisitions

Debt Restructuring

Debt-Equity Swaps

Financial Statements

Debt Restructuring

Exchange Agreement

Financial Results

Loan Amendments

Financing Update

Stock Split Approval

Loan Agreement Update

Loan Agreement Update

Financial Results

Bridge Financing Update

Bonus Extension

Bridge Loan Secured

Financial Results

Consent Agreement, Bridge L...

Loan Amendment and Consent ...

Note Amendment and Consent ...

Agreement and Loan Amendment

Compliance with Nasdaq List...

Loan Restructuring

Earnings Report

Loan and Security Agreement

Earnings Report

Registered Direct Offering

Departure of Directors or C...

Evaluation of Strategic Alt...

Note Purchase Agreement

Private Placement

Amendment and Appointment

Appointment of Chief Operat...

Exchange Agreement

FDA Clearance for Venus Ver...

Private Placement

Earnings Release

Amendment to Senior Preferr...

Private Placement

Earnings Report

Reverse Stock Split

Earnings Report

Departure of Chief Operatin...

Results of Operations and F...

Departure of CEO

External Links:

On November 10, 2025, Venus Concept Inc. announced it received FDA clearance to market its new Venus Nova multi-application platform for non-invasive body and skin treatments.

AI Assistant

VENUS CONCEPT INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.